Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of pulsed inhaled nitric oxide in symptomatic pulmonary arterial hypertension
MOH_2017-05-10_000318Phase 3Completed
- Sponsor
- Bellerophon Therapeutics
- Start
- Mar 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Placebo with Pulsed inhaled nitric oxide (2 arms). Started Mar 2016; status: completed.
02
Drugs
nitric oxide
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2017-05-10_000318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-10_000318.